Ratings Omda

Equities

CSAM

NO0010894512

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-06 am EDT			5-day change	1st Jan Change
35.9 ^NOK	0.00%		+4.06%	-2.97%

Apr. 25	Omda AS Announces Board Appointments	CI
Mar. 01	Tranche Update on Omda AS (OB:OMDA)'s Equity Buyback Plan announced on January 30, 2023.	CI

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company has a low valuation given the cash flows generated by its activity.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an expected P/E ratio at 79.98 and 32.05 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OMDA	-2.97%	67.68M		-
VEEVA SYSTEMS INC.	+5.52%	32.83B		C
PRO MEDICUS LIMITED	+18.02%	7.73B		C-
SECTRA AB	+23.16%	3.96B		B-
EVOLENT HEALTH, INC.	-17.53%	3.12B		C-
OMNICELL, INC.	-20.33%	1.38B		B
LUNIT INC.	-30.65%	1.2B		-
SIMULATIONS PLUS, INC.	+7.73%	963M		C
B-SOFT CO.,LTD.	-33.44%	934M		-
VERADIGM INC.	-26.60%	829M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes